Newly Issued Japanese Patent For PDC Optical Agents Further Strengthens Cellectar Biosciences’ Intellectual Property Portfolio

MADISON, Wis., March 14, 2017 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces the Japanese Patent Office has granted a composition of matter …
( read original story …)

---